Wilpen250 mg

Wilpen is a chelating agent with established and guideline-supported uses in the following conditions:

Established Indications

• Wilson's disease (hepatolenticular degeneration): First-line chelation therapy to reduce toxic copper accumulation in the liver, brain, and other tissues.
• Cystinuria: Used in patients with severe cystine stone disease when conservative measures (high fluid intake, urinary alkalinization, dietary sodium/protein restriction) fail to keep urinary cystine below the level required to prevent stone formation.
• Severe, active rheumatoid arthritis: Indicated in patients who have failed an adequate trial of conventional therapy (e.g., NSAIDs, other disease-modifying antirheumatic drugs) and cannot tolerate or benefit from those agents. Due to newer, better-tolerated disease-modifying antirheumatic drugs (DMARDs), Wilpen is now used much less frequently for this indication.

Wilpen is not used for infections and has no antimicrobial activity, despite its structural relationship to the penicillin nucleus.

Each tablet/capsule contains Penicillamine as the active ingredient, commonly available in 125 mg and 250 mg oral strengths. Inactive excipients vary by manufacturer.

Wilpen is a thiol-containing chelating agent derived from penicillin, but it has no antibacterial activity of its own. It is used both to bind and remove excess copper or cystine from the body, and separately as a slow-acting disease-modifying agent in severe rheumatoid arthritis. It is given orally and is generally prescribed for long-term, specialist-supervised treatment of chronic conditions such as Wilson's disease, cystinuria, and rheumatoid arthritis.

Wilpen belongs to the class of chelating agents (heavy metal antagonists) and, for its rheumatologic use, is classified as a slow-acting disease-modifying antirheumatic drug (DMARD).

Penicillamine is a thiol-containing chelating agent. In Wilson's disease, it combines with copper to form a stable, water-soluble complex that is readily excreted in the urine, lowering the toxic free-copper burden. In cystinuria, it undergoes a thiol-disulfide exchange reaction with cystine to form a mixed disulfide that is more soluble than cystine itself, reducing the risk of stone formation. In rheumatoid arthritis, the exact mechanism of Penicillamine is not fully understood; proposed effects include lowering circulating IgM rheumatoid factor, altering collagen cross-linking, and modulating T-cell function, producing a slow-onset immunomodulatory effect that may take 2-3 months to become apparent.

Wilpen should be taken orally on an empty stomach, at least 1 hour before or 2 hours after food, and kept apart by at least 1 hour from milk, antacids, iron, or zinc supplements to prevent reduced absorption. Swallow tablets/capsules whole with water.

Clinically significant interactions with Wilpen include:

• Antacids, iron, zinc, and other mineral supplements: Chelate with Wilpen in the gut, reducing its absorption; separate administration by at least 2 hours.
• Gold therapy, antimalarials (e.g., chloroquine, hydroxychloroquine), and immunosuppressants: Concomitant use with Wilpen increases the risk of serious hematologic and renal toxicity; generally avoided in combination.
• Other nephrotoxic or bone-marrow-suppressing drugs: Additive risk of blood dyscrasias or kidney injury when combined with Wilpen.
• Digoxin: Wilpen may reduce serum digoxin concentrations.

Common

• Nausea, vomiting, loss of appetite
• Taste disturbance (metallic taste or loss of taste), usually reversible
• Mouth ulcers, skin rash, itching

Serious (require prompt medical attention)

• Bone marrow suppression: leukopenia, thrombocytopenia, or aplastic anemia (fever, sore throat, unusual bruising/bleeding)
• Proteinuria and nephrotic syndrome
• Autoimmune reactions: myasthenia gravis-like syndrome, systemic lupus erythematosus-like syndrome, Goodpasture-like syndrome
• Optic neuritis (rare)

Regular laboratory monitoring is used during Wilpen therapy to detect these serious effects early (see Precautions and Warnings).

Wilpen should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus, under the direct supervision of a specialist. Wilpen is contraindicated in pregnant women being treated for rheumatoid arthritis because of teratogenic risk, including reported connective-tissue and skin abnormalities in the fetus. In Wilson's disease, Wilpen is sometimes continued cautiously through pregnancy at a reduced dose because abrupt discontinuation can cause severe hepatic decompensation, but this decision must be made and monitored by a specialist. Wilpen passes into breast milk in small amounts; breastfeeding is generally not recommended during treatment unless a physician determines the benefit outweighs the risk.

• Hematologic monitoring: Wilpen can cause bone marrow suppression. Complete blood counts (including platelets) should be checked every 2 weeks for the first several months, then monthly thereafter; discontinue Wilpen if significant cytopenia occurs.
• Renal monitoring: Urinalysis should be checked regularly to detect proteinuria, an early sign of Wilpen-induced nephrotoxicity; use with caution and reduced doses in patients with renal impairment.
• Autoimmune reactions: Monitor for symptoms of myasthenia gravis-like syndrome, lupus-like syndrome, or other autoimmune phenomena; discontinue Wilpen if these occur.
• Vitamin B6 deficiency: Wilpen can cause pyridoxine deficiency; supplementation is usually recommended with prolonged use.
• Penicillin allergy: Use Wilpen with caution in patients with a history of penicillin hypersensitivity due to possible cross-reactivity.
• Wilson's disease: Abrupt discontinuation of Wilpen can precipitate acute hepatic decompensation; do not stop treatment without medical advice.

Overdose of Wilpen may cause nausea, vomiting, and an increased risk of the serious adverse effects described above. There is no specific antidote. If an overdose of Wilpen is suspected, seek immediate medical attention or contact a poison control center; treatment is supportive and should only be directed by medical professionals.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

Use Wilpen with caution and close monitoring in patients with renal impairment; it is contraindicated for the rheumatoid arthritis indication in patients with significant renal insufficiency.

Hepatic Impairment

No specific dose-adjustment guidelines for Wilpen are well established in hepatic impairment; use with caution and clinical monitoring.

Elderly

No specific dose adjustment of Wilpen is required in elderly patients, but renal function and blood counts should be monitored closely given the higher likelihood of age-related renal decline.

Duration of Wilpen therapy depends on the condition being treated. Wilson's disease and cystinuria typically require lifelong maintenance therapy. For rheumatoid arthritis, a trial of at least 2-3 months is generally needed to assess response, and Wilpen is continued only if benefit is demonstrated and tolerability is acceptable; therapy should never be stopped abruptly without consulting the prescribing physician.

Chelating agent; disease-modifying antirheumatic drug (DMARD).

Penicillamine chelates copper and other heavy metals, forming soluble complexes that are excreted in urine, and forms a soluble mixed disulfide with cystine to reduce stone formation in cystinuria. Its antirheumatic effect is thought to involve immunomodulatory effects on T-cells and reduction of circulating rheumatoid factor, though the precise mechanism of Penicillamine in rheumatoid arthritis is not fully understood. See Pharmacology for details.

D

Wilpen is used in children with Wilson's disease and cystinuria, with dosing calculated on a weight basis under specialist supervision (commonly around 20 mg/kg/day in divided doses for Wilson's disease, adjusted to clinical and laboratory response). Safety and efficacy of Wilpen for rheumatoid arthritis, including juvenile idiopathic arthritis, have not been well established in children, and it is not routinely used for this indication in pediatric patients. Regular hematologic and renal monitoring is essential in all pediatric patients receiving Wilpen.